Yangtze River Pharmaceutical Group

Taizhou, China

Yangtze River Pharmaceutical Group

Taizhou, China

Time filter

Source Type

News Article | November 30, 2016
Site: www.newsmaker.com.au

This report studies sales (consumption) of United States Glimepiride market, focuses on the top players, with sales, price, revenue and market share for each player, covering Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Glimepiride in each application, can be divided into View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/united-states-glimepiride-market-report-2016 United States Glimepiride Market Report 2016 1 Glimepiride Overview 1.1 Product Overview and Scope of Glimepiride 1.2 Classification of Glimepiride 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Glimepiride 1.3.11 Blood sugar for people with type 2 diabetes 1.3.2 Application 2 1.3.3 Application 3 1.4 United States Market Size Sales (Value) and Revenue (Volume) of Glimepiride (2011-2021) 1.4.1 United States Glimepiride Sales and Growth Rate (2011-2021) 1.4.2 United States Glimepiride Revenue and Growth Rate (2011-2021) 5 United States Glimepiride Manufacturers Profiles/Analysis 5.1 Sanofi-Aventis 5.1.1 Company Basic Information, Manufacturing Base and Competitors 5.1.2 Glimepiride Product Type, Application and Specification 5.1.2.1 Type I 5.1.2.2 Type II 5.1.3 Sanofi-Aventis Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.1.4 Main Business/Business Overview 5.2 Wanbang Biopharmaceuticals 5.2.2 Glimepiride Product Type, Application and Specification 5.2.2.1 Type I 5.2.2.2 Type II 5.2.3 Wanbang Biopharmaceuticals Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.2.4 Main Business/Business Overview 5.3 Cspc Pharmaceutical 5.3.2 Glimepiride Product Type, Application and Specification 5.3.2.1 Type I 5.3.2.2 Type II 5.3.3 Cspc Pharmaceutical Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.3.4 Main Business/Business Overview 5.4 Tianan Pharmaceutical 5.4.2 Glimepiride Product Type, Application and Specification 5.4.2.1 Type I 5.4.2.2 Type II 5.4.3 Tianan Pharmaceutical Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.4.4 Main Business/Business Overview 5.5 Yangtze River Pharmaceutical Group 5.5.2 Glimepiride Product Type, Application and Specification 5.5.2.1 Type I 5.5.2.2 Type II 5.5.3 Yangtze River Pharmaceutical Group Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.5.4 Main Business/Business Overview 5.6 Takeda Pharms USA 5.6.2 Glimepiride Product Type, Application and Specification 5.6.2.1 Type I 5.6.2.2 Type II 5.6.3 Takeda Pharms USA Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.6.4 Main Business/Business Overview 5.7 Teva 5.7.2 Glimepiride Product Type, Application and Specification 5.7.2.1 Type I 5.7.2.2 Type II 5.7.3 Teva Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.7.4 Main Business/Business Overview 5.8 Dr Reddys Labs Ltd 5.8.2 Glimepiride Product Type, Application and Specification 5.8.2.1 Type I 5.8.2.2 Type II 5.8.3 Dr Reddys Labs Ltd Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.8.4 Main Business/Business Overview Global QYResearch is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


Market Research Report Provides Manufacturers Profiles/Analysis: Novartis, Pfizer, Inc., Roche, Sanofi, Merck & Co., Inc., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca plc., Eli Lilly and Company, Abbvie, AMGen, Teva Pharmaceutical Industries Ltd., Bayer AG, Bristol-Myers Squibb, Astellas Pharma, Daiichi Sankyo, Abbott Laboratories, Yangtze River Pharmaceutical Group, BAX & more -with detail like Company Basic Information, Manufacturing Base and Competitors. The report provides a basic overview of Lipid Regulating Drugs industry including definitions, applications and industry chain structure. United States market analysis and Chinese domestic market analysis are provided with a focus on history, developments, trends and competitive landscape of the market. A comparison between the international and Chinese situation is also offered. United States Lipid Regulating Drugs Industry Research Report 2016 also focuses on development policies and plans for the industry as well as a consideration of a cost structure analysis. Capacity production, market share analysis, import and export consumption and price cost production value gross margins are discussed. A key feature of this report is it focus on major industry players, providing an overview, product specification, product capacity, production price and contact information for United States Top15 companies. This enables end users to gain a comprehensive insight into the structure of the international and Chinese Lipid Regulating Drugs industry. Development proposals and the feasibility of new investments are also analyzed. Companies and individuals interested in the structure and value of the Lipid Regulating Drugs industry should consult this report for guidance and direction. The report begins with a brief overview of the United States Lipid Regulating Drugs market and then moves on to evaluate the key trends of the market. The key trends shaping the dynamics of the United States Lipid Regulating Drugs market have been scrutinized along with the related current events, which is impacting the market. Drivers, restraints, opportunities, and threats of the United States Lipid Regulating Drugs market have been analyzed in the report. Moreover, the key segments and the sub-segments that constitutes the market is also explained in the report.


PubMed | Yangtze River Pharmaceutical Group, Peking Union Medical College and China Pharmaceutical University
Type: Journal Article | Journal: Chinese journal of natural medicines | Year: 2016

An LC-MS/MS method was developed and validated for the simultaneous quantification of chlorogenic acid (CGA) and taurocholic acid (TCA) in human plasma using hydrochlorothiazide as the internal standard. The chromatographic separation was achieved on a Hedera ODS-2 column with a gradient elution using 10 mmolL(-1) of ammonium acetate buffer solution containing 0.5% of formic acid - acetonitrile as mobile phase at a flow rate of 300 Lmin(-1). The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring in negative ESI mode. The method was fully validated over the concentration ranges of 0.1-10 ngmL(-1) for CGA and 2-150 ngmL(-1) for TCA. It was successfully applied to a pharmacokinetic study of CGA and TCA in healthy Chinese volunteers after oral administration of Shuanghua Baihe tablets (SBTs). In the single-dose study, the maximum plasma concentration (Cmax), time to reach Cmax (Tmax) and elimination half-life (t1/2) of CGA were (0.763 8 0.542 0) ngmL(-1), (1.0 0.5) h, and (1.3 0.6) h, respectively. In the multiple-dose study, the Cmax, Tmax and t1/2 of CGA were (0.663 7 0.583 3) ngmL(-1), (1.1 0.5) h, and (1.4 0.7) h, respectively. For TCA, no significant characteristic increasing plasma TCA concentration-time curve was found in the volunteers after oral administration of SBTs, indicating its complicated process in vivo as an endogenous ingredient.


PubMed | Yangtze River Pharmaceutical Group, Peking Union Medical College, National Key Institute of Traditional Chinese Medicine Quality Control and China Pharmaceutical University
Type: | Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | Year: 2016

Corynoline and acetycorynoline, the major active components derived from Corydalis bungeana Herba, showed multiple pharmacological activities. However, quantification of the two compounds in human urine has not been reported. A simple liquid chromatography with tandem mass spectrometry method for the simultaneous determination of corynoline and acetycorynoline in human urine has been developed and fully validated. The analytes were extracted from urine samples by simple liquid-liquid extraction. Chromatographic separation was achieved on a Hedera ODS-2C18 column with the mobile phase of water (containing 0.5% formic acid) and acetonitrile (28:72, v/v) at a flow rate of 0.4mL/min. A tandem mass spectrometric detection was conducted using multiple reaction monitoring via an electrospray ionization source in positive mode. The monitored ion transitions were m/z 368.1289.1 for corynoline, m/z 410.2289.2 for acetycorynoline and m/z 380.2243.2 for donepezil (internal standard), respectively. The calibration curves were linear (correlation coefficients>0.9970) over the concentration ranges of 3.0-3000pg/mL for corynoline and 3.0-1000pg/mL for acetycorynoline. The established method was highly sensitive with the lower limit of quantification (LLOQ) of 3.0pg/mL for both analytes. The intra- and inter-day precision was lower than 10% in terms of relative standard deviation for the low, medium, and high quality control samples, and lower than 16% for the LLOQ samples of the analytes. The accuracy was within 10% in terms of relative error for both analytes. The method was successfully applied to a urinary excretion study after oral administration of the Chinese medicine formula Shuanghua Baihe tablets in healthy volunteers. The urinary excretion profiles of corynoline and acetycorynoline in human were first reported. The results of this study suggest that renal excretion was not the main excretion pathway of corynoline and acetycorynoline in humans.


This report studies sales (consumption) of Global Vitamin Drugs Market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Vitamin Drugs in these regions, from 2011 to 2021 (forecast), like North America China Europe Japan Southeast Asia India Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Fat-soluble Vitamins Water-soluble Vitamins Type III Split by applications, this report focuses on sales, market share and growth rate of Vitamin Drugs in each application, can be divided into First Level Hospital Two Level Hospital Three Level Hospital Others 1 Vitamin Drugs Overview 1.1 Product Overview and Scope of Vitamin Drugs 1.2 Classification of Vitamin Drugs 1.2.1 Fat-soluble Vitamins 1.2.2 Water-soluble Vitamins 1.2.3 Type III 1.3 Applications of Vitamin Drugs 1.3.1 First Level Hospital 1.3.2 Two Level Hospital 1.3.3 Three Level Hospital 1.3.4 Others 1.4 Vitamin Drugs Market by Regions 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Vitamin Drugs (2011-2021) 1.5.1 Global Vitamin Drugs Sales, Revenue and Price (2011-2021) 1.5.2 Global Vitamin Drugs Sales and Growth Rate (2011-2021) 1.5.3 Global Vitamin Drugs Revenue and Growth Rate (2011-2021) 9 Global Vitamin Drugs Manufacturers Analysis 9.1 Novartis 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Vitamin Drugs Product Type and Technology 9.1.2.1 Fat-soluble Vitamins 9.1.2.2 Water-soluble Vitamins 9.1.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.2 Pfizer, Inc. 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Vitamin Drugs Product Type and Technology 9.2.2.1 Fat-soluble Vitamins 9.2.2.2 Water-soluble Vitamins 9.2.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.3 Roche 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Vitamin Drugs Product Type and Technology 9.3.2.1 Fat-soluble Vitamins 9.3.2.2 Water-soluble Vitamins 9.3.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.4 Sanofi 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Vitamin Drugs Product Type and Technology 9.4.2.1 Fat-soluble Vitamins 9.4.2.2 Water-soluble Vitamins 9.4.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.5 Merck & Co., Inc. 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Vitamin Drugs Product Type and Technology 9.5.2.1 Fat-soluble Vitamins 9.5.2.2 Water-soluble Vitamins 9.5.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.6 GlaxoSmithKline plc 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Vitamin Drugs Product Type and Technology 9.6.2.1 Fat-soluble Vitamins 9.6.2.2 Water-soluble Vitamins 9.6.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.7 Johnson & Johnson 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Vitamin Drugs Product Type and Technology 9.7.2.1 Type I 9.7.2.2 Type II 9.7.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2017) 9.8 AstraZeneca plc. 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Vitamin Drugs Product Type and Technology 9.8.2.1 Type I 9.8.2.2 Type II 9.8.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2018) 9.9 Eli Lilly and Company 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 Vitamin Drugs Product Type and Technology 9.9.2.1 Type I 9.9.2.2 Type II 9.9.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2019) 9.10 Abbvie 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 Vitamin Drugs Product Type and Technology 9.10.2.1 Type I 9.10.2.2 Type II 9.10.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2021) 9.11 AMGen 9.12 Teva Pharmaceutical Industries Ltd. 9.13 Bayer AG 9.14 Bristol-Myers Squibb 9.15 Astellas Pharma 9.16 Daiichi Sankyo 9.17 Abbott Laboratories 9.18 Yangtze River Pharmaceutical Group 9.19 Taish? Seiyaku Kabushiki-gaisha Global QYResearch (http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


This report studies sales (consumption) of Global Sex Hormones and Birth Control Pills Market 2016, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Sex Hormones and Birth Control Pills in these regions, from 2011 to 2021 (forecast), like North America China Europe Japan Southeast Asia India Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Male Hormone Drugs Female Hormone Drugs Progesterone Drugs Split by applications, this report focuses on sales, market share and growth rate of Sex Hormones and Birth Control Pills in each application, can be divided into First Level Hospital Two Level Hospital Three Level Hospital Others 1 Sex Hormones and Birth Control Pills Overview 1.1 Product Overview and Scope of Sex Hormones and Birth Control Pills 1.2 Classification of Sex Hormones and Birth Control Pills 1.2.1 Male Hormone Drugs 1.2.2 Female Hormone Drugs 1.2.3 Progesterone Drugs 1.3 Applications of Sex Hormones and Birth Control Pills 1.3.1 First Level Hospital 1.3.2 Two Level Hospital 1.3.3 Three Level Hospital 1.3.4 Others 1.4 Sex Hormones and Birth Control Pills Market by Regions 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Sex Hormones and Birth Control Pills (2011-2021) 1.5.1 Global Sex Hormones and Birth Control Pills Sales, Revenue and Price (2011-2021) 1.5.2 Global Sex Hormones and Birth Control Pills Sales and Growth Rate (2011-2021) 1.5.3 Global Sex Hormones and Birth Control Pills Revenue and Growth Rate (2011-2021) 9 Global Sex Hormones and Birth Control Pills Manufacturers Analysis 9.1 Novartis 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.1.2.1 Male Hormone Drugs 9.1.2.2 Female Hormone Drugs 9.1.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.2 Pfizer, Inc. 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.2.2.1 Male Hormone Drugs 9.2.2.2 Female Hormone Drugs 9.2.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.3 Roche 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.3.2.1 Male Hormone Drugs 9.3.2.2 Female Hormone Drugs 9.3.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.4 Sanofi 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.4.2.1 Male Hormone Drugs 9.4.2.2 Female Hormone Drugs 9.4.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.5 Merck & Co., Inc. 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.5.2.1 Male Hormone Drugs 9.5.2.2 Female Hormone Drugs 9.5.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.6 GlaxoSmithKline plc 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.6.2.1 Male Hormone Drugs 9.6.2.2 Female Hormone Drugs 9.6.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.7 Johnson & Johnson 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.7.2.1 Type I 9.7.2.2 Type II 9.7.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2017) 9.8 AstraZeneca plc. 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.8.2.1 Type I 9.8.2.2 Type II 9.8.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2018) 9.9 Eli Lilly and Company 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.9.2.1 Type I 9.9.2.2 Type II 9.9.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2019) 9.10 Abbvie 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.10.2.1 Type I 9.10.2.2 Type II 9.10.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2021) 9.11 AMGen 9.12 Teva Pharmaceutical Industries Ltd. 9.13 Bayer AG 9.14 Bristol-Myers Squibb 9.15 Astellas Pharma 9.16 Daiichi Sankyo 9.17 Abbott Laboratories 9.18 Yangtze River Pharmaceutical Group 9.19 Taish? Seiyaku Kabushiki-gaisha Global QYResearch (http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


Peng J.,China Pharmaceutical University | Qi X.,China Pharmaceutical University | Chen Y.,China Pharmaceutical University | Ma N.,China Pharmaceutical University | And 6 more authors.
Journal of Drug Targeting | Year: 2014

Purpose: An octreotide-conjugated polyamidoamine (PAMAM) dendrimer was synthesized and employed as nanocarriers of methotrexate (MTX), for targeting to the somatostatin receptors over-expressed tumor cells. Methods: PAMAM-PEG-octreotide (PPO) and PAMAM-PEG (PPG) were synthesized and characterized. The cellular uptake of fluorescein isothiocyanate (FITC)-labeled PPO (PPO-FITC) and PPG (PPG-FITC) were investigated. The cytotoxicity of MTX and MTX nanoparticles were conducted in the MCF-7 cells. Besides, the pharmacokinetics studies on MTX nanoparticles were carried out in rats. Results: The structure of PPO was verified by NMR detection and the diameter was 11.05 ± 1.80 nm, with the amount of MTX encapsulated by PPO was 30 (molecule/molecule). MTX nanoparticles possessed significantly higher cytotoxicity against MCF-7 cells compared with free MTX, especially the PPO/MTX nanoparticles. Correspondingly, the PPO-FITC carrier had higher cellular uptake efficiency compared to PPG-FITC. In addition, pharmacokinetics studies showed that PPO/MTX nanoparticles increased mean residence time and bioavailability of MTX distinctly. Discussion and conclusion: With further cellular uptake test of FITC-labeled carriers, the enhanced cytotoxicity of PPO/MTX nanoparticles was reasonable to ascribe to the specific receptor-mediated endocytosis induced by octreotide. The present study suggests that this PAMAM-PEG-octreotide nanocarrier opens a new path for treating cancer with higher efficacy. © 2014 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted.


Zhang T.,Shenyang Pharmaceutical University | Sun Y.,Shenyang Pharmaceutical University | Zhang P.,Shenyang Pharmaceutical University | Gao J.,Yangtze River Pharmaceutical Group | And 2 more authors.
Biomedical Chromatography | Year: 2013

A rapid, sensitive and selective ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the determination of febuxostat in dog plasma. Using paclitaxel as an internal standard (IS), a simple liquid-liquid extraction method with ethyl acetate was adopted for plasma sample pretreatment. Separation was carried out on an Acquity UPLC BEH C18 column with a mobile phase consisting of acetonitrile and water (containing 0.2% formic acid). The assay was linear in the concentration ranged from 5 to 5000 ng/mL with a lower limit of quantification of 5 ng/mL for febuxostat. The single run analysis was as short as 2.0 min. Finally, the developed method was successfully applied to the pharmacokinetic study of febuxostat tablets following oral administration at a single dose of 40 mg in beagle dogs. © 2012 John Wiley & Sons, Ltd.


Qi X.,China Pharmaceutical University | Jiang Y.,China Pharmaceutical University | Zhang H.,China Pharmaceutical University | Wu Z.,China Pharmaceutical University | Wu Z.,Yangtze River Pharmaceutical Group
Journal of Pharmacy and Pharmacology | Year: 2015

Objectives The aim of this study was to prepare a disintegrating gastric floating tablet composed of floating pellets coated with acrylic resin to prolong the gastric residence time and increase the oral bioavailability of famotidine. Methods The gastric floating pellets containing famotidine, stearyl alcohol and microcrystalline cellulose (1 : 10 : 1) were prepared by extrusion-spheronization process and coated with acrylic resin, then compressed into tablets with Avicel PH 301 pellets and cross-linked polyvinylpyrrolidone. The coating weight, volume ratio of Eudragit RL30 D and RS30 D and solid content of coating fluid were optimized by Box-Behnken design. Key findings In 0.1 M HCl, tablets can immediately disintegrate into pellets which can remain floating and sustained drug releasing over 12 h. The AUC0-∞ of famotidine gastric floating pellets (7776.52 ± 1065.93 h ng/ml) administered into rats was significantly higher than that of marketed rapid release tablets Xingfading® (Xingyi, Shanghai, China) (4166.23 ± 312.43 h ng/ml), while the relative bioavailability was 187.01 ± 22.81%. Conclusions The experimental results indicated that the optimized formulation did offer a new gastro retention and sustained release approach to enhance the oral absorption of famotidine. © 2014 Royal Pharmaceutical Society.


Qi X.,China Pharmaceutical University | Qin J.,China Pharmaceutical University | Ma N.,China Pharmaceutical University | Chou X.,China Pharmaceutical University | And 2 more authors.
International Journal of Pharmaceutics | Year: 2014

The aims of this study were to choose a suitable adsorbent of self-microemulsion and to develop a fine solid self-microemulsifying dispersible tablets for promoting the dissolution and oral bioavailability of celastrol. Solubility test, self-emulsifying grading test, droplet size analysis and ternary phase diagrams test were performed to screen and optimize the composition of liquid celastrol self-microemulsifying drug delivery system (SMEDDS). Then microcrystalline cellulose KG 802 was added as a suitable adsorbent into the optimized liquid celastrol-SMEDDS formulation to prepare the dispersible tablets by wet granulation compression method. The optimized formulation of celastrol-SMEDDS dispersible tablets was finally determinated by the feasibility of the preparing process and redispersibility. The in vitro study showed that the dispersible tablets could disperse in the dispersion medium within 3 min with the average particle size of 25.32 ± 3.26 nm. In vivo pharmacokinetic experiments of rats, the relative bioavailability of celastrol SMEDDS and SMEDDS dispersible tablets compared to the 0.4% CMC-Na suspension was 569 ± 7.07% and 558 ± 6.77%, respectively, while there were no significant difference between the SMEDDS and SMEDDS dispersible tablets. The results suggest the potential use of SMEDDS dispersible tablets for the oral delivery of poorly water-soluble terpenes drugs, such as celastrol. © 2014 Published by Elsevier B.V. All rights reserved.

Loading Yangtze River Pharmaceutical Group collaborators
Loading Yangtze River Pharmaceutical Group collaborators